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SUMMARY 
 
The induction of cytotoxic T lymphocyte (CTL) responses is of high relevance in 
immunological defense against intracellular pathogens and tumor cells. While humoral 
immune responses are successfully induced by a number of vaccines, the activation of 
cellular immune responses has only been addressed more recently.  
The development of novel immunogens from live attenuated vaccines to subunit vaccines 
demands efficient and safe adjuvants to improve their immunogenicity. Importantly, there 
are only three adjuvants licensed for human use: aluminium salts, MF59 (microfluidized 
detergent stabilized oil in water emulsion) and IRIV (immunopotentiating reconstituted 
influenza virosomes). Aluminium salts are the most widely used adjuvants and their 
efficacy in enhancement of humoral responses is well documented. They are ineffective in 
the induction of cellular responses, whereas IRIV and MF59 might be effective, in addition 
to humoral responses, also in the induction of cellular responses. 
The aim of our group, working in the field of cancer immunotherapy, is induction of CTL 
specific to melanoma associated antigens. The monitoring of a clinical phase I/II trial has 
demonstrated increased frequencies of specific CTL in peripheral blood upon 
administration of antigenic epitopes encoded as minigenes with costimulatory molecules in 
a recombinant vaccinia virus. In the heterologous vaccination protocol adopted, however, 
high CTL frequencies were not sustained upon administration of the same epitopes as 
synthetic peptides. This pattern prompted the search for appropriate adjuvants enhancing 
peptide induced CTL responses. 
In this thesis work we focused on the in vitro characterization of immune responses elicited 
by influenza virosomes and on the in vitro evaluation of influenza virosome adjuvance in 
HLA class I restricted  peptide induced CTL responses. We tested empty IRIV admixed 
with peptides and influenza virosomes encapsulating peptides, both produced by Pevion 
Biotech Ltd. Due to the low encapsulation efficiency of IRIV per se, the production of the 
second formulation required encapsulation of peptides into liposomes and subsequent 
fusion with chimeric IRIV. Thus, we characterised immune responses elicited by empty 
IRIV and empty chimeric IRIV fused with empty liposomes (FCIRIV). Then, we evaluated 
their adjuvant capacity by testing CTL induction in the presence of IRIV admixed with 
peptides and by peptides encapsulated in FCIRIV as compared to CTL induction by 
peptides in absence of influenza virosomes.  
For IRIV admixed with peptides we addressed induction of CTL specific for the highly 
immunogenic Influenza matrix 58-66 (IM58-66) and to the immunodominant melanoma 
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associated Melan-A/ Mart-127-35  HLA-A201 restricted epitopes. For peptides encapsulated 
in FCIRIV we addressed induction of CTL specific for the L27Melan-A/Mart-126-35  HLA-
A0201 restricted epitope.  
Our results demonstrate that all influenza virosome formulations under investigation 
induce antigen triggered CD4+ T cell proliferation characterized by a T helper 1 cytokine 
profile. Further dissection of CD4+ T cells identified CD4+CD45RO+ cells as proliferative 
responders to IRIV stimulation and no major cell proliferation could be induced in cord 
blood mononuclear cell cultures. These findings indicate that the majority of CD4+ T cells 
responding to IRIV  are antigen experienced. In addition, supernatants of IRIV stimulated 
PBMC cultures favoured maturation of dendritic cells, as demonstrated by upregulation of 
HLA-ABC, CD86 and CD83.  
Both, influenza virosomes admixed with peptides or encapsulating peptides significantly 
enhanced specific CTL induction, as detected by multimer staining and cytotoxicity assays. 
CTL induction experiments in presence of irradiated CD4+ T cells indicated that IRIV CTL 
adjuvance required CD4+ T cell activation. In addition, transwell cultures pointed to a key 
role of cytokines in IRIV mediated CTL adjuvance. 
In contrast to empty IRIV, FCIRIV with encapsulated peptides were characterized by CD4+ 
T cell independent adjuvant potential, possibly attributable to influenza virosome delivery 
capacities.  
Taken together, our results demonstrate that influenza virosomes are endowed with the 
capacity to enhance HLA class I restricted CTL induction in vitro. Importantly, this could be 
demonstrated not only for the highly immunogenic IM58-66 epitope, but also for the 
melanoma associated epitopes L27Melan-A/Mart-126-35 and Melan-A/Mart-127-35.  
Moreover, CTL induced by L27Melan-A/Mart-126-35 encapsulated in FCIRIV were capable of 
recognizing and lysing tumor cells that constitutively express the Melan-A/Mart-1 antigen. 
These in vitro findings encourage further evaluation of influenza virosome CTL adjuvance 
in vivo. 
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INTRODUCTION 
 
The identification of the first tumor associated antigen (TAA) in 1991 [1] has represented 
the starting point for the performance of clinical trials aiming to activate the adaptive 
immune system against various kinds of tumors by expanding TAA specific cytotoxic T 
lymphocytes (CTL).  
In this regard it should be emphasized that the development of „T cell vaccines“ is still in 
its infancy as compared to the majority of existing vaccines which mainly act through the 
humoral arm of the immune sytem. Especially chronic viral infections like HIV and HCV 
and tumors have raised wide attention regarding the possibility of generating specific 
cellular immune responses. The forte of activated specific CTL may be represented by 
their ability to kill infected cells or tumor cells, possibly resulting in reduced spread of the 
infectious agent or regression of tumors, respectively. In contrast to humoral responses 
the induction of CTL responses is dependent on histocompatibility antigens which are 
highly polymorphic. Thus, responsiveness among different individuals might display a high 
variability, depending on the antigen and the individual HLA class I phenotype.  
Major limitations of T cell vaccines, as reported for viral infections, are the ability of 
pathogens to escape T cell response by mutating target epitopes and the potential for T 
cells to become exhausted by high levels of persisting antigen [2]. Moreover, priming of 
CTL requires, in addition to TCR recognition of the epitope-HLA complex, a costimulatory 
signal provided by the APC. Provision of both signals is crucial, as absence of 
costimulation usually results in anergy of specific CTL.  
Technically, the development of T cell vaccines is also challenged by difficulties in 
monitoring CTL responses eventually induced. Surrogate markers for efficacy and 
protection  are frequently unclear [2] and in vitro assays require short- to medium-term 
stimulation in vitro. 
Regarding induction of TAA specific CTL,  it should be noted that tumors are part of the 
„self“ and therefore are likely to be tolerated by the immune system.  
Administration of TAA derived peptides demands formulations that, in the best case 
provide protection from enzymatic degradation, access to antigen presenting cells and 
enhancement of peptide induced CTL response. Considering the latter, there are very few 
adjuvants approved for human use, all with proven efficacy in humoral immune responses. 
Our group has performed a phase I/II clinical trial in melanoma by using a heterologous 
vaccination protocol [3]. HLA-A0201 restricted epitopes of the TAA Melan-A/Mart-1 (27-
35), gp100 (280-288) and tyrosinase (1-9) were administered subcutaneously either as 
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minigenes encoded together with costimulatory molecules by an inactivated, 
nonreplicating recombinant vaccinia virus (TAA - rVV) or as synthetic peptides [3]. In 
addition, GM-CSF was administered as supporting cytokine. The heterologous protocol 
was chosen to minimize immune responses against rVV that may hamper the capacity of 
the recombinant virus to infect antigen presenting cells. Monitoring of TAA specific CTL 
frequency in peripheral blood demonstrated an increase upon TAA-rVV administration 
which was not sustained upon peptide administration. 
The decrease of TAA specific CTL frequency upon peptide administration may be due to 
low stability and poor immunogenicity of synthetic peptides as such. Furthermore, at 
difference with the TAA-rVV formulation, HLA class I restricted peptides per se do not 
provide CD4+ T cell help.  
This pattern initiated the search for adjuvants appropriately enhancing CTL responses 
induced by synthetic peptide formulations.  
We focused on Immunopotentiating Reconstituted Influenza Virosomes (IRIV), one of the 
very few adjuvants approved for human use beside aluminium salts and MF-59 
(microfluidized detergent stabilized oil in water emulsion) [4].  
Influenza virosomes in general were first described by Almeida et al. in 1975 [5]. 
IRIV, produced by Pevion Biotech Ltd. (Berne, Switzerland), are used as adjuvant in 
hepatitis A vaccination and as subunit vaccine in influenza vaccination. They are spherical 
150nm sized particles, consisting of a phospholipid bilayer in which influenza virus derived 
hemagglutinin (HA) and neuraminidase (NA) are intercalated. Basically, these particles 
mimick structurally and functionally the envelope of influenza virus (Fig. Introduction 1, 
panels A, B and C).  
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Fig. Introduction1. Schematic and electron microscopical presentation of influenza virosomes. 
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Regarding functional properties, influenza virus derived HA plays a key role in virosome 
uptake by APC through receptor mediated endocytosis and in intracellular fusion of the 
virosome with the endosomal membrane [6]. Moreover, it is a highly immunogenic antigen 
derived from a widespread and frequently occuring pathogen. Finally, the spherical 
structure of virosomes may be suitable to encapsulate peptides and protect them from 
enzymatic degradation. Whereas IRIV have been demonstrated to enhance humoral 
responses in hepatitis A vaccination [7-9], little is known on their adjuvant capacity as 
related to CTL responses. In studies on hepatitis C it has been shown that IRIV containing 
HLA class I restricted HCV core peptides can prime CTL from peripheral blood 
mononuclear cells of HCV- healthy blood donors in vitro [10]. These primed CTL were 
capable of recognizing and lysing HCV infected target cells, but no major adjuvance was 
observed as compared to priming with peptides alone. However, in a more recent study in 
vivo adjuvance in the induction of HCV core peptide specific CTL could be demonstrated 
in mice by using chimeric IRIV containing the HCV core 132 peptide [11]. Moreover, in vivo 
administration of influenza virosomes encapsulating a murine CTL epitope of the influenza 
virus nucleoprotein (NP) was shown to enhance the induction of a class I MHC-restricted 
CTL response against influenza-infected cells as compared to administration of soluble 
peptides [12]. This adjuvant effect has been shown to require the membrane fusion activity 
of influenza virosomes, as fusion-inactivated virosomes and NP-peptide mixed with empty 
virosomes did not induce CTL activity. Recently, influenza virosomes have been 
demonstrated to enhance CTL induction against virosome-encapsulated ovalbumin (OVA) 
in mice as well [13]. 
In summary, Influenza virosome CTL adjuvance has been demonstrated in mice  using 
formulations including encapsulated peptides or proteins.  
The goal of this work was to characterize IRIV elicited immune responses and to evaluate 
IRIV adjuvant capacity in relation to CTL induction. Unlike previous studies we addressed 
immunological effects of IRIV per se and investigated TAA specific CTL responses in 
human cell cultures.  
 
Regarding TAA, MAGE-1, detected in 1991 in melanoma, was the first gene reported to 
encode a human tumor antigen recognized by T cells [1]. One year later, the first HLA 
class I restricted epitope, a nonapeptide encoded by MAGE-1, was characterized [14]. 
Since then, identification and characterization of novel HLA class I and HLA class II 
restricted TAA has rapidly evolved. According to their tissue distribution, TAA are classified 
in cancer-testis antigens, differentiation antigens, widely occurring, overexpressed TAA 
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and unique and shared tumor-specific antigens [15]. All melanoma associated epitopes 
used in our clinical trial, Melan-A/ Mart-127-35, gp100280-288 and tyrosinase1-9 are derived 
from differentiation antigens. These TAA are shared between tumors and the normal 
tissue from which the tumor arose. Most are detectable in melanomas and normal 
melanocytes [15].  
Among the epitopes used in our clinical trial, Melan-A/Mart-127-35  is the most and 
tyrosinase the least immunogenic. In this work we focused on Melan-A/Mart-1 specific CTL 
induction, using the nonapeptide  Melan-A/Mart-127-35 and the more immunogenic 
decapeptide analog L27Melan-A/Mart-126-35 as epitopes. Considering the variability of 
Melan-A/Mart-1 specific CTL precursor frequencies among healthy donors, we first 
investigated IRIV CTL adjuvance in relation to influenza matrix58-66 specific CTL induction. 
As influenza virus is a frequently occurring and widespread pathogen, IM58-66 specific CTL 
may be present in PBMC of most HLA-A0201+ healthy donors. Thus, CTL induction 
experiments were performed focusing on IM58-66, Melan-A/Mart-127-35 and L27Melan-A/ 
Mart-126-35 HLA-A0201 restricted epitopes. 
IRIV CTL adjuvance was evaluated using two different formulations, both produced by 
Pevion Biotech Ltd.: Empty IRIV admixed with soluble peptides and chimeric IRIV (CIRIV) 
encapsulating peptides. The step from empty IRIV to peptide encapsulating CIRIV 
required an elegant circumventing of the low peptide encapsulation efficiency (0.1-2%) of 
IRIV per se [11]. As liposomes display a much higher peptide encapsulation efficiency (15-
20%), peptides were first encapsulated in liposomes. In parallel empty CIRIV including 
hemagglutinin derived from two influenza virus strains (X-31 and A/Sing) were produced. 
Finally, these empty CIRIV were fused with peptide encapsulating liposomes at acidic pH 
and18°C, a temperature at which only the X-31 deriv ed HA is active and suffices for the 
fusion process.  This procedure resulted in peptide encapsulation into CIRIV with native 
HA derived from A/Sing influenza virus and inactivated HA derived from X-31 influenza 
virus (Peptide-FCIRIV: Peptide encapsulated into CIRIV fused with liposomes). 
 
Before evaluating IRIV CTL adjuvance we aimed at characterizing immune responses 
elicited in vitro by IRIV per se, in absence of peptides. Here we addressed cell 
proliferation, cytokine profile and IRIV effects on antigen presenting cells in PBMC cultures 
of healthy donors. Then, we tested IRIV mediated CTL adjuvance in relation to IM58-66 and 
Melan-A/Mart-127-35 using empty IRIV admixed with peptides as compared to peptides 
alone. Finally, FCIRIV adjuvance was evaluated, using FCIRIV encapsulating  
L27Melan-A/Mart-126-35 as compared to non-encapsulated L27Melan-A/Mart-126-35  peptide in 
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solution. As FCIRIV differ from IRIV in their hemagglutinin and lipid content we evaluated 
in parallel, same as for IRIV, immune responses elicited by this formulation in absence of 
encapsulated peptides. 
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MATERIALS AND METHODS 
 
 
 
1. Influenza virosome formulations 
 
 
IRIV   (Immunopotentiating Reconstituted Influenza Virosomes) 
CIRIV  (Chimeric Immunopotentiating Reconstituted Influenza Virosomes) 
FCIRIV (CIRIV fused to empty liposomes) 
Mart-FCIRIV  (FCIRIV with encapsulated L27Melan-A/Mart-126-35) 
 
(All from Pevion Biotech Ltd., Bern, Switzerland) 
 
1.1 Preparation of IRIV 
Egg phosphatidylcholine (PC, 32 mg), (Lipoid GmbH,Ludwigshafen, Germany) and 
phosphatidylethanolamine (PE, 8 mg), (R. Berchtold, Biochemisches Labor, Bern, 
Switzerland) were dissolved in 2.66 ml of PBS containing 100mM octaethyleneglycol 
(OEG) (Fluka Chemicals,Switzerland), (PBS-OEG). The influenza A/Singapore 
hemagglutinin was purified as described previously [16]. A solution containing 2mg 
hemagglutinin was centrifuged for 30 min at 100,000 × g and the pellet was dissolved 
in 1.33 ml of PBS-OEG. The phospholipids and the hemagglutinin-solution were mixed 
and sonicated for 1 min. This mixture was then centrifuged for 1 h at 100,000 × g and the 
supernatant sterile filtered (0.22 µ). Detergent was removed by using SM Bio-Beads 
(BioRad, Hercules, PA). Control liposomes (L) were similarly produced, in the absence of 
influenza virus components. 
 
1.2 Preparation of CIRIV 
Chimeric virosomes with hemagglutinin (HA) from the X-31 and the A/Sing Influenza 
strain, respectively, were prepared by the methods described previously [11,17,18]. Briefly, 
32 mg egg PC and 8 mg PE were dissolved in 2 ml of PBS (10.4 µmol/ml PC; 2.7 µmol/ml 
PE),  100 mM OEG (PBS/OEG). 4 mg HA of each influenza virus was centrifuged at 
100,000 x g for 1 h at 4°C and the pellet was dissolved in 2 m l of PBS/OEG. The detergent 
solubilised phospholipids and viruses were mixed and sonicated for 1 min. This mixture 
was centrifuged at 100,000 x g for 1 h at 20°C and the supernatant  was sterile filtered (0.22 
µm). Virosomes were then formed by detergent removal using 1.24 g of wet SM2 Bio-
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Beads for 1 h at room temperature with shaking and three times for 30 min with 0.62 g of 
SM2 Bio-Beads each. 
 
 
1.3 Preparation of liposomes encapsulating peptides 
25.4 µmol (19.5 mg) PC and 11.5 µmol (8.2 mg) DPPG (molar ratio 70:30) were dissolved in 
methanol/chloroform (2:1). The solvent was removed by a rotary evaporator (Rotavapor R-
205, Büchi Labortechnik, Switzerland) at 40°C at a gradual vacuum of 30-10 kPa. The 
dried lipid film was hydrated with 250 µl PBS containing 0.4 mg L27Melan-A/Mart-126-35 
peptide to be encapsulated. Several identical preparations were pooled for extrusion. The 
liposome suspension was extruded four times through polycarbonate membranes 
(Nucleopore Track-Etch membrane, 0.2 µm, Whatman, UK) with a 1.5 ml Lipex Extruder 
(Northern Lipids, Canada). Size determination of extruded liposomes was performed by 
light scattering using a Zetasizer 1000HS instrument (Malvern Instruments, UK). 
 
 
1.4 Preparation of Mart-FCIRIV 
CIRIVs (290 µl in PBS, approx. 2.9 mg phospholipid) were incubated with 160 µl (approx. 
17 mg phospholipid) of PC/DPPG extruded liposomes (0.2 µm diameter) containing the 
L27Melan-A/Mart-126-35  peptide at 18°C in PBS under constant stirring. To  trigger fusion 
the pH was adjusted to 5.0 ± 0.2 with 1 M HCl. After incubation for 20 min, the mixture was 
neutralised with 1 M NaOH to a pH of 7.4 ± 0.2 and fusion products were extruded five 
times through polycarbonate membranes (Nucleopore Track-Etch membrane, 0.2 µm) with 
a 1.5 ml Lipex Extruder (Northern Lipids, Canada). 
 
 
Hemagglutinin content of all influenza virosome formulations ranged between  
0.5 mg/ml and  2 mg/ml. 
 
L27Melan-A/Mart-126-35 stock concentration of the Mart-FCIRIV formulation was  
100 µg/ml. 
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2. HLA-A0201 restricted peptides     Sequence 
 
IM58-66  (Neosystem, Strasbourg, France)    GILGFVFTL 
Melan-A/Mart-127-35 (Neosystem, Strasbourg, France)  AAGIGILTV 
L27Melan-A/Mart-126-35 (Bachem AG, Bubendorf, Switzerland) ELAGIGILTV 
 
 
 
 
3. Cell culture 
 
 
3.1 Isolation of PBMC  
Peripheral blood mononuclear cells (PBMC) were obtained from heparinized blood by 
gradient centrifugation according to standard methods. 
 
 
 
 
 
3.2 Culture of PBMC  
PBMC were cultured in:  
 
RPMI 1640 (with L-Glutamine, GIBCO) supplemented with 
 
Kanamycin (100µg/ml)  
Hepes buffer 10mM 
Sodium pyruvate MEM 1mM  
Glutamax 1mM  
MEM Non essential amino acids 
 
All from GIBCO Paisley, Scotland, thereafter referred to as complete medium (CM) 
 
5% human serum (HS, Blutspendezentrum, University Hospital Basel, Switzerland) 
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3.3 Isolation of PBMC cell subsets 
 
Isolation of PBMC cell subsets was perfomed by magnetic cell separation (Miltenyi 
Biotech, Bergisch Gladbach, Germany) according to producers‘ protocols. 
 
 
3.4 Generation of monocyte derived immature dendritic cells (iDC) 
 
CD14+ cells were isolated from peripheral blood of healthy donors and cultured for 5 to 7 
days in DC-medium in 6 well plates (1 x 106 to 1.5 x 106 cells per well). DC medium drives 
the differentiation from CD14+ cells to immature dendritic cells (iDC) and was prepared as 
follows: 
 
RPMI 1640 (with L-Glutamine) supplemented with 
 
 
Kanamycin (100µg/ml)  
Sodium pyruvate MEM 1mM  
Glutamax 1mM  
MEM Non essential amino acids 
 
All from GIBCO Paisley, Scotland 
 
10% fetal calf serum (GIBCO) 
0.004% (v/v) β-mercaptoethanol 
IL-4 (1000 U/ml, courtesy of Dr. Lanzavecchia, Bellinzona, Switzerland) 
 50 ng/ml GM-CSF (Novartis, Basel, Switzerland). 
 
  
4. Assays 
 
 
4.1 Proliferation assays  
Cells were cultured in CM 5% HS in 96 well flat bottom plates (Becton Dickinson, Le Pont 
de Claix, France) at 2 x 105 cells/ well. On day 5 (antigenic stimulation of peripheral blood 
cells) or 2 (mitogenic stimulation) 3H-thymidine (Amersham, Little Chalfont, UK) was added 
at 1µCi per well. After a further incubation for 18 hours, cells were harvested and tracer 
incorporation was measured by beta counting. Finally, cell proliferation was expressed as 
3H-thymidine incorporation in counts per minutes (cpm). 
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4.2 Phenotyping by flow cytometry 
 
Cells were washed in PBS and 2µl fluorescent labeled (FITC or PE) antibodies (BD 
Biosciences Pharmingen) were added to each sample. Fluorescent labeled mouse 
immunoglobulin isotype controls were used to exclude unspecific background staining. 
Following incubation for 30 minutes on ice in the dark, cells were washed twice, 
resuspended in 200µl PBS and acquired by a flow-cytometer (FACScalibur) equipped with 
Cell Quest software (Becton Dickinson, San Diego, CA). 
 
 
4.3 CTL induction  
 
CD14- cells were cocultured with iDC (CD14- cells : iDC ratio ranged from 5:1 to 20:1) in 
presence of the HLA class I restricted peptide (IM58-66 : 1-2 µg/ml, Melan-A/Mart-127-35: 
10µg/ml,  L27Melan-A/Mart-126-35: 0.25–2µg/ml final concentration) with or without influenza 
virosomes. In case of IM58-66 CTL induction was evaluated 6 to 8 days after setup without 
IL-2 supplementation and without restimulation. 
For Melan-A/Mart-127-35 and L27Melan-A/Mart-126-35 CTL induction was evaluated after IL-2 
supplementations and one restimulation with irradiated peptide pulsed APC. IL-2 
supplementations were usually performed at 10-20 units/ ml on days 4, 5 and 6 and at 100 
units/ml on days 7 and 10. Restimulation was usually performed on day 7 as follows: 
autologous iDC or CD14+ cells were incubated for 2-3 hours at 37°C in presence of 10 µg 
peptide/ml. After incubation cells were irradiated (CD14+ cells: 3500 rad, iDC: 2500 rad), 
washed and added to the assay cultures. 
 
Evaluation of CTL induction was performed by multimer staining  and/or 51Cr release 
cytotoxicity assays. Regarding IM58-66, limiting dilution analysis of CTL precursor frequency 
was also performed (see below). 
 
 
4.3.1 Multimer staining 
Cells were washed once in PBS and supernatants discarded. 
Following addition of 1µl PE labeled pentamers (Proimmune, Oxford, UK), samples were 
incubated  for 10-20 min. at room temperature in the dark. After one wash in PBS 2µl FITC 
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labeled anti-CD8 were added to each sample and all samples were incubated for 30 min. 
on ice in the dark. 
Following two washes in PBS, cells were resuspended in 200µl PBS  and acquired by a 
flow-cytometer (FACScalibur) equipped with Cell Quests software (Becton Dickinson, San 
Diego, CA). 
CTL induction was evaluated by quantification of the percentages of tetramer/pentamer 
positive CD8+ cells within the whole CD8+ cell population. 
 
When tetramers were used, the staining procedure was performed in one step: 
After wash, tetramers PE and anti-CD8 FITC were added simultaneously to each sample 
and all samples were incubated for 45 minutes at 4°C in the dark.  
 
 
 
 
4.3.2 Cytotoxicity assays 
 
Target cells (NA-8 cells, T2 cells or HBL cells) were washed in PBS and resuspended in 
0.2ml  complete medium supplemented with 10% FCS (RPMI 10% FCS). Following 51Cr 
pulsing (100µCi per sample, 1 hour at 37°C) target cells were wa shed twice in PBS, 
resuspended in RPMI 10% FCS and preincubated with the target or control peptide (2 
hours at 37°C in the waterbath, 10 µg peptide/ml). After incubation cells were washed once 
in PBS and resuspended in RPMI 10% FCS. 
During preincubation with peptides effector cells were plated in 96 well round bottom 
plates (Becton Dickinson, Le Pont de Claix, France). At least 20 min. before addition of 
target cells 100'000 K562 cells per well were added to effector cells in a volume of 50µl 
each. Target cells (1000 per well in a volume of  50µl each)  were then added. Plates were 
centrifuged to provide cell : cell contact between target and effector cells and incubated at 
37°C for 4 hours. After incubation supernatants fro m each well were transferred into 
corresponding wells of Luma plates (Perkin Elmer, Boston, MA). Dried Luma plates were 
read by a microplate scintillation and luminescence counter. 
 
Percentage of specific lysis was evaluated by the following formula: 
% cytotoxicity = sample value – spont value / max value – spont value x 100 
spont value: value of spontaneous release 
max value: value of maximal release 
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4.3.3 Limiting dilution assays 
 
CD8+ cells were cocultured in 96 well round bottom plates (Becton Dickinson, Le Pont de 
Claix, France) with irradiated CD8- cells pulsed with individual peptides.  
CD8+ cells were plated in different cell numbers as follows: columns 1-4 (32 wells): 
maximal CD8+ cell number per well ranging between 5000 and 10000; columns 5-8 (32 
wells): ½ maximal CD8+ cell number per well ranging between 2500 and 5000; columns 9-
12 (32 wells): ¼ maximal CD8+ cell number per well ranging between 1250 and 2500. 
CD8- cells were plated in constant numbers (70'000 per well) into each well. Final volume 
of cell suspension per well was 200µl. Antigenic formulations were added and the plates 
incubated at 37°C, 5% CO 2. Further procedures included IL-2 supplementation (20 
units/ml) on day 3, restimulation with antigenic peptide and second IL-2 supplementation 
(20 units/ml) on day 7, a third IL-2 supplementation (100 units/ml) on day 10 and 
cytotoxicity assay on day 15. Cytotoxicity assays were performed by splitting each well in 
two for assays with specific or control peptides, respectively. Epitope specific CTL 
precursor frequency was measured by evaluating numbers of positive wells (displaying at 
least 12% specific cytotoxicity) according to the Poisson’s formula.  
 
 
4.4 Cytokine gene expression assays 
 
PBMC were harvested at different times of culture and total RNA was extracted by using 
an RNeasy Mini Kit (Qiagen). 
For conventional PCR, total RNA was reverse transcribed as follows: 2µg RNA, 2µl oligo d 
(T) and RNAse free water were mixed in a total volume of 24 µl and incubated  at 65 °C for 
10 minutes in the waterbath. Samples were then immediately put on ice and supplemented 
with a mix of 2µl dNTP (2.5 mM), 4µl DTT (100mM, Gibco BRL),  8µl 5x first strand buffer 
(Gibco BRL) and 2µl M-MLV reverse transcriptase (200 U/ml, Gibco BRL). Samples were 
incubated at 37°C for 90 minutes in the waterbath. Subsequently the M-MLV reverse 
transcriptase was inactivated by heating the samples at 94 °C for 5 minutes and cDNA 
samples were stored at –70°C.   
 
PCRs were performed as follows:  
 
Primary denaturation of the templates by 10 min heating at 95°C 
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Amplification cycles included the following protocoll: 
40 sec denaturation at 94°C, 40 sec annealing at 62 °C, 1 min extension at 72°C. 
 
Final extension was performed by 15 min heating at 72°C.  
 
Primers [19]: 
 
β-actin  Sense primer:  TGACGGGGTCACCCACACTGTGCCCATCTA 
  Antisense primer: CTAGAAGCATTGCGGTGGACGATGGAGGG 
 
IL-2  Sense primer:  ATGTACAGGATGCAACTCCTGTCTT 
  Antisense primer: GTCAGTGTTGAGATGATGCTTTGAC   
 
IL-4  Sense primer:  ATGGGTCTCACCTCCCAACTGCT 
  Antisense primer: CGAACACTTTGAATATTTCTCTCTCAT 
 
IL-5  Sense primer:  GCTTCTGCATTTGAGTTTGCTAGCT 
  Antisense primer: TGGCCGTCAATGTATTTCTTTATTAAG 
 
 
IL-10  Sense primer:  AAGGCATGCACAGCTCAGCACT 
  Antisense primer: TCCTAGAGTCTATAGAGTCGCCA 
 
TNF-α  Sense primer:  ATGAGCACTGAAAGCATGATCCGG 
  Antisense primer: GCAATGATCCCAAAGTAGACCTGCCC 
 
IFN-γ  Sense primer:  ATGAAATATACAAGTTATATCTTGGCTTT 
  Antisense primer: GATGCTCTTCGACCTCGAAACAGCAT 
 
GM-CSF Sense primer:  ACACTGCTGAGATGAATGAAACAGTAG 
  Antisense primer: TGGACTGGCTCCCAGCAGTCAAAGGGGATG 
 
In case of CIRIV and FCIRIV formulations expression of IFN-γ and IL-4 genes was 
addressed by one step real time PCR. Briefly, ∆CT [CT (gene of interest) – CT (reference 
gene GAPDH)] was calculated for each sample and reference sample. ∆∆CT [∆CT 
(reference sample) – ∆CT (sample)] was evaluated, and relative quantification was 
calculated as 2-∆∆CT. The results were expressed as n-fold difference relative to the 
reference sample.Real-Time qPCR were performed in Thermofast® 96 well plates 
(Abgene, Epsom, UK), using the TaqMan® One Step PCR Master Mix Reagents Kit 
(Applied Biosystems, Forster City, CA) and the ABI primTM 7700 sequence detection 
system (Applied Biosystems, Forster City, CA).  
Stage1: 2 min. at 50°C, stage2: 10 min. at 95°C, st age3: 15 sec. at 95°C followed by 1 
min. at 60°C (repeated 45 times). Normalization of sample was performed using GAPDH 
as reference gene.  
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Primers and Probes: 
GAPDH [20]: Fwd ATG GGG AAG GTG AAG GTC G 
  Rev TAA AAG CAG CCC TGG TGA CC 
  Probe FAM-CGC CCA ATA CGA CCA AAT CCG TTG AC-TAMRA 
   
 
IFN-γ [21]: Fwd AGC TCT GCA TCG TTT TGG GTT 
  Rev GTT CCA TTA TCC GCT ACA TCT GAA 
  Probe FAM-TCT TGG CTG TTA CTG CCA GGA CCC A-TAMRA 
   
 
IL-4 [22]: Fwd CCA CGG ACA CAA GTG CGA TA 
  Rev CCC TGC AGA AGG TTT CCT TCT 
  Probe TCTGTGCACCGAGTTGACCGTAACAGAC 
 
 
IL-6:  Fwd CAG CCC TGA GAA AGG AGA CAT G 
  Rev GGT TCA GGT TGT TTT CTG CCA 
  Probe AGT AAC ATG TGT GAA AGC AGC AAA GAG GCA C-TAMRA 
 
Quantification of cytokine gene expression was calculated by using a reference sample for 
comparison of gene expression in experimental samples.  
IL-6 gene expression was addressed by real time PCR following separately performed 
reverse transcription, using the TaqMan® Universal PCR Master Mix , No AmpErase® 
UNG (Applied Biosystems, Forster City, CA). 
 
 
4.5 Cytokine secretion assays 
Supernatants of PBMC cultures were harvested at different times of culture and cytokine 
concentrations analysed by standard ELISA assays. Either  BD OptEIA TM ELISA Sets 
(Becton Dickinson, Franklin Lakes, NJ) or reagents from BD Pharmingen (BD Pharmingen, 
San Diego, CA) were used according to company’s descriptions. Data were analyzed 
using Softmax software (Molecular Devices Corporation, Menlo Park, CA). 
 
4.6 General remarks 
 
Data displayed are usually representative for at least two independently performed 
experiments, except those indicated as preliminary and those displayed in Fig. 3. 
Standard deviations of all cytotoxicity assays and real time PCR assays were below 10% 
and are not displayed in the figures. 
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RESULTS 
 
 
PART 1: STUDIES ON EMPTY IRIV 
 
I. Immune responses elicited by IRIV in PBMC 
 
To characterize immune responses elicited by IRIV in vitro we addressed cell proliferation, 
cytokine gene expression and secretion as well as effects on antigen presentation. 
 
 
1. IRIV induce antigen specific proliferation of CD4+CD45RO+ cells 
 
PBMC from healthy donors were cultured in the presence of IRIV at different 
concentrations and proliferation was measured as 3H-thymidine incorporation after 6 days 
incubation. Upon IRIV stimulation cell proliferation could be observed in PBMC cultures 
from all (n = 10) donors tested. One representative experiment is presented in Fig. 1, A . 
The extent of 3H-thymidine incorporation was variable in cultures from different donors but 
no PBMC proliferation was detectable in cultures performed in the presence of control 
liposomes (L) devoid of viral proteins.  
To address the identity of proliferating cells proliferation assays were performed with 
purified CD4+ T cells or CD8+ T cells cocultured with autologous irradiated PBMC in 
presence and absence of IRIV. 
As shown in Fig. 1, B CD4+ T cells but not CD8+ T cells proliferated in presence of IRIV. 
Further dissection of CD4+ cells into CD45RA+ and CD45RO+ cells indicated that 
CD4CD45RO+ T cells represented the main cell population responding to IRIV stimulation 
(Fig. 2, B). The CD45RO+ phenotype is characteristic for memory T cells and therefore 
these data indicate that IRIV induced cell stimulation is of antigenic nature. This 
observation is corroborated by proliferation assays performed with cord blood 
mononuclear cell cultures in presence of IRIV or conventional mitogens. As shown in Fig. 
2, A  both mitogens PHA and Con A induced marked cell proliferation. In contrast, IRIV 
only induced a marginal 3H-thymidine incorporation in naive cells, similar to that detectable 
in cultures performed in the presence of control L. 
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Fig. 1 
 
IRIV induce cell proliferation in PBMC cultures and CD4+ T cells were identified as proliferative responders. 
Panel A: PBMC from healthy donors (n=3) were cultured in the absence of stimuli (Neg), in the presence of 
IRIV (V) and in the presence of control liposomes (L) at the indicated dilutions. Proliferation was measured on 
day six of culture by 3H-thymidine incorporation. Panel B: Purified CD4+ or CD8+ cells were cocultured with 
autologous irradiated PBMC in the absence of stimuli (Neg) and in the presence of IRIV (V) at the indicated 
concentrations. Proliferation was measured on day six of culture by 3H-thymidine incorporation. 
A. 
B. 
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IRIV induce antigen specific proliferation of CD4+CD45RO+ cells. Panel A: cord blood mononuclear cells from two 
donors were cultured in the absence of stimuli (Neg) or in the presence of PHA, ConA, IRIV (V) or liposomes (L) at 
the indicated concentrations. Proliferation was measured on day three of culture for PHA and ConA stimulated 
cultures and on day six for IRIV and L stimulated cultures by 3H-thymidine incorporation. Panel B: Purified 
CD4+CD45RA+ cells and CD4+CD45RO+ cells were isolated from PBMC of one healthy donor and cocultured with 
autologous irradiated PBMC in the presence of IRIV (V) or liposomes (L) at the indicated concentration. 
Proliferation was measured on day six of culture by 3H-thymidine incorporation. 
A. 
B. 
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To further verify antigen dependence of IRIV induced cell proliferation we addressed CD4+ 
T cell proliferation in presence and absence of APC. As shown in Fig. 3, IRIV induced 
marginal cell proliferation in absence of APC, whereas major cell proliferation was 
observed only in presence of APC after 6 days of culture (panel B). In contrast, PHA, used 
as mitogen positive control, induced strong proliferation of CD4+ cells in absence of APC 
(panel A), measured after 3 days of culture. No cell proliferation could be observed in 
absence of any stimuli (Neg).
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Fig. 3 
 
CD4+ cell proliferation in absence and presence of APC, induced by IRIV. 
CD4+ cells of one healthy donor’s PBMC were cultured in presence or absence of autologous CD14+ cells  
in 96well flat bottom plates. Following incubation with either IRIV  (1:160 diluted) or PHA (1µg/ml), mitogen 
induced cell proliferation was measured on day 3 (panel A), IRIV induced cell proliferation on day 6 (panel 
B) by 3H-thymidine incorporation. 
IRIV (-APC): IRIV stimulated CD4+ cell cultures in absence of APC (CD14+ cells). 
IRIV  (+APC): IRIV stimulated CD4+/CD14+ cell cocultures 
 
 
A. 
B. 
(-APC) 
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2. IRIV induce typical T helper 1 cytokine gene expression and secretion profiles  
PBMC from healthy donors were cultured in presence or absence of IRIV. On day 1 and 2 
cells and supernatants were harvested. RT- PCR with cytokine specific primers 
demonstrated expression of IFN-γ, GM-CSF, TNF-α and IL-2 genes in PBMC upon IRIV 
stimulation (Fig. 4) whereas no expression of IL-4, IL-5 and IL-10 genes could be 
observed. IFN-γ gene expression could be observed on day 2, but not on day 1 whereas 
expression of GM-CSF, TNF-α and IL-2 could be observed on day 1 and 2 of culture. 
ELISA assays performed with supernatants harvested on day 1, 2 and 4 of culture 
demonstrated increased secretion of IFN-γ, GM-CSF, TNF-α, but not of IL-4 in PBMC 
upon IRIV stimulation (Fig. 5 A-D). IFN-γ concentration in supernatants of IRIV stimulated 
PBMC cultures increased after day 2 of culture, whereas TNF-α concentration was at its 
peak on day 1 and decreased with time. GM-CSF concentration in supernatants of IRIV 
stimulated PBMC did not vary much within 4 days of culture. 
These results demonstrate an IRIV induced cytokine expression pattern in PBMC culture 
characteristic of a T helper 1 immune response. The different kinetics of cytokine gene 
expression and secretion suggest that TNF-α and GM-CSF expression represent „early 
events“ whereas IFN-γ expression represents a later event of IRIV induced lymphocyte 
activation.  
Another indication suggesting the notion of an IRIV induced T helper 1 response results 
from the quantification of CD4+ T cells expressing CXCR3, a chemokine receptor 
characteristic for inflammatory and T helper 1 responses [23]. Healthy donor‘s PBMC 
cultured in presence of IRIV displayed 56% CD4+CXCR3+ T cells within the CD4+ T cell 
population (Fig. 6, C) on day six of culture whereas PBMC cultured in presence of 
liposomes or in the absence of any formulation displayed 41% and 40% CD4+CXCR3+ T 
cells within the CD4+ T cell population, respectively. Thus, IRIV stimulation of PBMC 
induced an increase of CD4+ T cells expressing CXCR3. 
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Fig. 4 
 
Cytokine gene expression in IRIV stimulated PBMC. PBMC were cultured  in the presence 
or absence of IRIV. On day one and two of culture, cells were harvested and total cellular 
RNA was extracted and reverse transcribed. The cDNAs thus obtained were tested in RT-
PCR assays in the presence of primers specific for the indicated cytokine genes. 
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Cytokine secretion in IRIV stimulated PBMC. PBMC from a healthy donor were cultured in the 
absence of stimuli (Neg) or in the presence of IRIV (V, 1:50 diluted) or control liposomes (L, 1:50 
diluted). On day one, two and four, supernatants were harvested and the concentrations of IFN-γ 
(Panel A), GM-CSF (Panel B), TNF-α (Panel C) and IL-4 (Panel D) were determined by ELISA.  
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Increased percentages of CXCR3+CD4+ T cells in IRIV stimulated PBMC. PBMC from a healthy 
donor were cultured in the absence of stimuli (panel a), in the presence of liposomes (1:50 final 
dilution, panel b) or IRIV (1:50 final dilution, panel c). After 6 days of culture, cells were phenotyped 
for the expression of CXCR3 and CD4 by PE and FITC labeled mAbs, respectively. Numbers 
indicate percentages of cells within each quadrant.  
40.2 41.1 
56 
In bold, percentages of CXCR3+ cells within the CD4+ cell population are shown. 
 31 
2. IRIV induce secretion of chemokines 
 
Then, we addressed secretion of chemokines, important factors for the recruitment of 
immunocompetent cells. 
We evaluated secretion of IP-10 (CXCL10), MIG (CXCL9) and Rantes (CCL5) in IRIV 
stimulated PBMC cultures by ELISA assays. All three chemokines were present in higher 
concentrations in IRIV (V) stimulated PBMC cultures as opposed to PBMC cultured in 
presence of liposomes (L) or in absence of any stimuli (Neg)  (Fig. 7). IP-10 (panel B) and 
MIG (panel A) concentrations in IRIV stimulated PBMC cultures increased over time 
reaching levels of 8900 pg/ml (V day 4) as compared to 1000 pg/ml (L, Neg) and 5100 
pg/ml (V day 5) as compared to 1300 pg/ml (L, Neg) respectively. Rantes (panel C) 
concentrations in IRIV stimulated PBMC cultures were higher than 10000 pg/ml on day 1 
and 2 and decreased to 6600 pg/ml on day 4. A decrease in Rantes concentrations over 
time was also observed in PBMC cultures performed in presence of liposomes (L: 5500 
pg/ml day 1 to 630 pg/ml day 4) and in absence of any stimuli (Neg: 2400 pg/ml day 1 to 
340 pg/ml day 4). The upregulation of IP-10, MIG and Rantes upon IRIV stimulation is 
intriguing, as these chemokines are involved in the recruitment of T lymphocytes [24-26]. 
In particular, MIG and IP-10 interact with CXCR3 [27], which has been shown to be 
expressed by CD4+ T cells responding to IRIV. The expression of these two chemokines 
is inducible by IFN-γ [27] which is also upregulated in IRIV stimulated PBMC.  
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Fig. 7 
 
Chemokine secretion in IRIV stimulated PBMC. PBMC from a healthy donor were cultured in the 
absence of stimuli (Neg) or in the presence of IRIV (V, 1:50 diluted) or control liposomes (L, 1:50 
diluted). At the indicated incubation times, supernatants were harvested and the concentrations of 
MIG (Panel A), IP-10 (Panel B) and Rantes (Panel C) were determined by ELISA. 
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3.  IRIV  effects on antigen presenting cells  
 
We then tested whether IRIV could directly or indirectly induce maturation of dendritic 
cells, highly professional antigen presenting cells. Immature dendritic cells (iDC) were 
incubated in presence or absence of IRIV and phenotyped after 24 and 48 hours for the 
surface expression of CD83, CD86 and HLA-ABC, molecules known to be increasingly 
expressed on mature dendritic cells (mDC) [28,29]. There was no major difference in 
expression of these maturation markers between iDC incubated in presence of IRIV and 
iDC incubated in absence of IRIV. However, when iDC were incubated with culture 
supernatants, expression of CD83, CD86 and HLA-ABC was upregulated on iDC 
incubated with supernatants from IRIV stimulated PBMC but not on iDC incubated with 
supernatants from non-stimulated PBMC (Fig. 8). These results demonstrate that IRIV do 
not directly induce maturation of dendritic cells but they induce secretion of cytokines in 
PBMC cultures that favour dendritic cell maturation. 
CD83 
CD86 HLA-ABC 
IDC + supernatant of non stimulated PBMC 
IDC + supernatant of IRIV stimulated PBMC 
Fig. 8 
Supernatants derived from IRIV stimulated PBMC induce upregulation of maturation markers 
on dendritic cells. Immature dendritic cells (iDC) were cultured in presence of supernatants 
derived from IRIV stimulated PBMC (lower histograms) or in presence of supernatants 
derived from non stimulated PBMC (upper histograms). After 48 hours cells were 
phenotyped for surface expression of CD83, CD86 and HLA-ABC as indicated. 
Supernatants were  added at a final 1:2 dilution. 
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II. IRIV adjuvance in CTL induction 
 
To evaluate IRIV adjuvance in CTL induction, cells were cultured in presence of HLA class 
I restricted epitopes with or without IRIV. Expansion of CTL specific for individual epitopes 
was evaluated by anti-CD8 FITC/  HLA-A0201/epitope tetramer PE double staining or, 
additionally, by limiting dilution assays addressing CTL precursors (CTLp) frequency.  
HLA class-A201 restricted epitopes from Influenza matrix (IM58-66) and from the tumor 
associated antigen Melan-A/Mart-1 (Melan-A/Mart-127-35) were used throughout the study. 
 
 
1.   IRIV adjuvance in IM58-66 specific CTL induction 
 
As IM58-66 is a highly immunogenic HLA-A0201 restricted epitope from the widespread 
influenza virus, its use facilitates short time CTL induction experiments without 
restimulation extended to a large range of donors. Thus, CTL induction experiments were 
first performed as related to IM58-66. 
As shown in Fig. 9 culture in presence of IRIV and IM58-66 strongly enhanced IM58-66 
specific CTL induction (7.6% IM58-66 specific CTL within the CD8+ T cell population, panel 
c) as compared to culture in presence of liposomes and IM58-66 (0.369%, panel b) or in 
presence of IM58-66 alone (0.179%, panel a), as evaluated on day 7 of culture by anti-CD8 
FITC/ IM58-66 tetramer PE double staining. Limiting dilution analysis of CTLp demonstrated 
that in cultures stimulated with IM58-66 and IRIV, 1/22.000 CD8+ T cells specifically 
recognized the target peptide (panel d) whereas no cytotoxicity was detectable in cultures 
stimulated with IM58-66 alone. In PBMC cultures stimulated with  
IM58-66 and liposomes, 1/84 wells showed evidence of specific cytotoxic activity, a 
frequency below the threshold evaluable by Poisson distribution. Taken together these 
results indicate that IRIV enhance the induction of functional IM58-66 specific CTL. 
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Fig. 9 
IRIV adjuvance on CTL induction. PBMC from a healthy donor were cultured in the presence of IM58–66 (a), 
IM58–66 and control liposomes (b) or IM58–66 and IRIV (c). After a 7 days culture, percentages of IM58–66 
specific CTL within cultured cells were quantified by HLA-A0201/IM58–66 PE tetramer staining (fluorescence 
2) and anti CD8 FITC staining (fluorescence 1). CTL precursor frequencies detected in IM58–66 and IRIV 
stimulated cultures within the same experiment are shown in panel d. 
 
7.6 
Bold numbers in panels a), b) and c) present percentages of tetramer positive cells within the CD8+ cell 
population. 
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2.   IRIV adjuvance in Mart-1/ Melan-A 27-35 specific CTL induction 
 
Enhancement of CTL induction is a major goal of cancer immunotherapy. Thus, we 
addressed whether IRIV adjuvance could be also observed in CTL induction specific for 
the tumor associated differentiation HLA-A0201 restricted epitope Melan-A/Mart-127-35. 
CD14- cells from healthy donors were cocultured with autologous iDC in presence of 
Melan-A/ Mart-127-35, in presence of Melan-A/ Mart-127-35 and liposomes and in presence of 
Melan-A/Mart-127-35 and IRIV. After one restimulation with Melan-A/Mart-127-35 pulsed iDC 
and further culture in presence of IL-2, cells were stained with anti-CD8 FITC and Melan-
A/Mart-127-35 tetramers PE on day 13. As shown in Fig 10, IRIV enhanced Melan-A/ Mart-
127-35 specific CTL induction as demonstrated by a higher percentage of Melan-A/Mart-127-
35 specific CTL within CD8+ T cells (11.38%, panel c)) in comparison with cell culture in 
presence of Melan-A/Mart-127-35 and liposomes (1.1%, panel b)) or Melan-A/ Mart-127-35 
alone (1.56%, panel a)). Thus, IRIV adjuvance was also observed in the induction of CTL 
specific for a tumor associated self epitope which is less immunogenic than the non self 
IM58-66 epitope.  
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Fig. 10 
Adjuvant effects of IRIV in the induction of tumour associated antigen specific CTL. CD14 negative 
cells from PBMC of a healthy donor were cocultured with autologous iDC in the presence of Melan-
A/Mart-127–35, alone (a) or supplemented with either control liposomes (b) or IRIV (1:50, c). On day 
seven of culture, cells were restimulated with Melan-A/MART-127–35 pulsed iDC and cultured for six 
further days (see material and methods). On day 13 cells were stained with FITC conjugated anti-CD8 
and PE conjugated HLA-A0201/Melan-A/MART-127–35 tetramers. Numbers represent percentages of 
cells within each quadrant. In bold, percentages of tetramer positive cells within the CD8+ cell 
population are shown. 
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3.   IRIV adjuvance in CTL induction is based on CD4+ T cell activation 
 
As previously described, proliferation experiments demonstrated that IRIV induce CD4+ T 
cell activation and expansion. We then asked whether CD4+ T cells capable to proliferate 
are required for IRIV mediated CTL adjuvance. To address this issue we cocultured CD8+ 
T cells, CD14+ cells and either irradiated or non-irradiated CD4+ T cells in presence of  
IM58-66 with or without IRIV. After one restimulation with irradiated IM58-66 pulsed CD14+ 
cells and further culture in presence of IL-2, cocultures were stained with anti-CD8 FITC 
and IM58-66 tetramers PE on day 13. As shown in Fig. 11, IRIV adjuvance could be 
observed in cocultures performed with non-irradiated CD4+ T cells (12.89% IM58-66 specific 
CTL within CD8+ T cells in presence of IM58-66 and IRIV as compared to 1.06% in 
presence of IM58-66 alone) but not in cocultures performed with irradiated CD4+ T cells 
(0.46% IM58-66 specific CTL within CD8+ T cells in presence of IM58-66 and IRIV as 
compared to 0.68% in presence of IM58-66 alone). These results demonstrate that IRIV CTL 
adjuvance is mediated through CD4+ T cell activation and expansion. 
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Fig. 11 
IRIV mediated adjuvance in CTL induction requires CD4+ T cells. 
CD8+ and CD14+ cells were cultured in the presence of autologous intact or irradiated CD4+ cells. These 
cultures were stimulated with influenza matrix 58-66 (1µg/ml) alone (A) or supplemented with IRIV (1:50) (B). 
After seven days of incubation both cocultures were restimulated with irradiated influenza matrix58-66 pulsed 
CD14+ cells and cultured for six further days in the presence of IL-2. Six days after restimulation cultures were 
stained with HLA-A0201/Influenza matrix 58-66 PE specific tetramers and anti CD8 FITC mAbs.  
Numbers represent percentages of cells within each quadrant. In bold, percentages of tetramer positive cells 
within the CD8+ cell population are shown. 
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4. Cytokines may play a major role in IRIV mediated CTL adjuvance  
(preliminary results) 
 
Induction of T helper 1 cytokines in IRIV stimulated PBMC cultures suggests that soluble 
factors may be key players in  IRIV CTL adjuvance. However, cell : cell contact dependent 
interactions (e.g. CD40 : CD40L) could provide a major contribution as well [30-33]. To 
address this issue we performed CTL induction experiments using 24 transwell plates with 
a membrane (0.1 µm pore size, corning costar) that allows diffusion of soluble factors but 
not cell : cell contact between upper and lower wells. Briefly, CD4+ T cells were cocultured 
with iDC in lower wells and CD8+ T cells with iDC in upper wells, all cells 
isolated/generated from blood of the same donor. Cocultures of lower and upper wells 
were each performed either in presence of IM58-66 alone or in presence of IM58-66 and IRIV. 
In parallel, cocultures were performed in control wells, allowing cell : cell contact 
dependent and cell : cell contact independent interactions. As shown in Fig.12 there was 
no major difference in CTL induction between transwell cocultures (panel D: 7.7% IM58-66 
specific CTL within CD8+ T cells) and control cocultures (panel C: 8.6%)  performed in the 
presence of IM58-66 and IRIV. CTL induction in presence of IM58-66 alone was lower, as 
compared to CTL induction in presence of IM58-66 and IRIV, in both, cocultures in 
transwells (panel C: 3.1% IM58-66 specific CTL within CD8+ T cells) and in control wells 
(panel A: 1.3%). A possible explanation for the higher percentage of IM58-66 specific CTL in 
transwell cocultures as compared to control cocultures could be represented by the 
absence of CD4+CD25+ T regulatory cell : cell contact dependent suppression in transwell 
cocultures  [34]. 
Taken together, these results suggest that cell : cell contact dependent interactions do not 
play a major role in IRIV CTL adjuvance in vitro whereas soluble factors appear to provide 
a major contribution. 
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Fig. 12 
Major role of soluble factors in IRIV mediated CTL adjuvance. 
IDC, CD4+ cells and CD8+ cells were cocultured in transwells ( panels C + D, lower wells: iDC and 
CD4+ cells, upper wells: iDC and CD8+ cells) or control wells (panels A + B) in presence of IM58-66 
(1µg/ml) or IM58-66 (1µg/ml) and IRIV (1:150). On day 7 cells were phenotyped for the expression of 
CD8 and IM58-66 specific TCR by anti-CD8 FITC/ IM58-66 tetramer PE double staining. Numbers display 
percentages of tetramer positive (upper right) and of tetramer negative (lower right) cells, in bold 
percentages of tetramer positive CD8+ cells within the CD8+ cell population are shown.  
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PART 2: STUDIES ON PEPTIDE CONTAINING INFLUENZA VIROSOMES 
 
III. Characterization and CTL adjuvance of  HLA class I restricted peptide containing 
influenza virosomes  
 
CTL induction experiments described previously were  performed by using soluble HLA 
class I restricted peptides, either added to cultures as such or admixed with empty IRIV. 
IRIV CTL adjuvance observed in these experiments was solely due to IRIV immunogenic 
properties and independent of IRIV delivery capacities. However, another approach to 
formulate the immunogenic epitope is to encapsulate it in influenza virosomes. Such a 
formulation would provide, in addition to IRIV own immunogenic properties, delivery of the 
epitope into the cytosol [6]. Moreover, the encapsulated epitope may be protected from 
enzymatic degradation by serum or cell surface associated peptidases, whereas the non-
encapsulated epitope, depending on its structure, is sensitive to degradation.  
These considerations urged the production of an influenza virosome formulation containing 
encapsulated L27Melan-A/Mart-126-35 peptide, an analog of the Melan-A/Mart-126-35 epitope 
with higher immunogenicity [35]. The production of this formulation was performed by 
Pevion Biotech Ltd. and required the overcoming of the poor encapsulation efficiency by 
IRIV per se [11]. To address this problem, the advantage of liposomes‘ high encapsulation 
efficiency was combined with the fusion activity of hemagglutinin derived from two 
influenza virus strains (X-31 and A/Sing). Briefly, so called chimeric IRIV (CIRIV) were 
produced by inclusion of hemagglutinins derived from influenza virus X-31 and from 
influenza virus A/Sing in the production process. At acidic pH and 18°C  temperature,  
these CIRIV were fused with liposomes containing the L27Melan-A/Mart-126-35 peptide. The 
fusion process under these conditions is mediated by X-31 hemagglutinin, as A/Sing 
hemagglutinin is active at 37°C but not 18°C. This fusion step finally results in L27Melan-
A/Mart-126-35 encapsulating fused CIRIV (Mart-FCIRIV) with conformationally modified and 
fusion incompetent  X-31 hemagglutinin and still native and fusion competent A/Sing 
hemagglutinin. 
The production of peptide containing FCIRIV leads to an influenza virosome formulation 
that, in addition to encapsulation of peptides, is different from IRIV regarding lipid content 
(higher) and hemagglutinin content (hemagglutinin derived from two different influenza 
virus strains). For this reason we first evaluated the immune responses elicited by the 
virosomal part of peptide containing FCIRIV. As for IRIV we addressed proliferation of 
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CD4+ T cells, cytokine expression of IFN-γ and IL-4, as well as quantification of CD4+ cells 
expressing CXCR3. This evaluation should clarify whether peptide encapsulating FCIRIV  
induce, like IRIV, CD4+ T cell proliferation with a T helper 1 profile. In proliferation assays 
and cytokine expression studies also intermediated stages in the production of peptide 
encapsulating FCIRIV were assayed (CIRIV, FCIRIV: CIRIV fused with empty liposomes). 
In parallel, CTL adjuvance of peptide encapsulating FCIRIV was addressed, using 
L27Melan-A/Mart-126-35 encapsulated in FCIRIV (Mart-FCIRIV ) as priming formulation. 
 
 
 
 
1. Mart-FCIRIV induce CD4+ T cell proliferation  
 
CD4+ and CD14+ cells isolated from peripheral blood of healthy donors were cultured in 
the absence of stimuli or in the presence of empty chimeric IRIV (CIRIV), empty chimeric 
IRIV fused with empty liposomes (FCIRIV), or chimeric IRIV fused to liposomes containing 
the Leu27 26-35 epitope from Melan-A/MART-1 melanoma associated antigen (Mart-
FCIRIV) at different dilutions. CIRIV and FCIRIV represent intermediate stages of the 
production of FCIRIV containing HLA class I restricted peptides. 
Upon a six days culture significant proliferation was induced by all preparations in all 
donors tested, the highest 3H-thymidine incorporation being usually detectable upon 
stimulation of PBMC with CIRIV. As previously described for IRIV, cells from different 
donors showed wide differences in their responsiveness to influenza virosome 
preparations.  Data reported in figure 13, panels A and B are representative of results 
obtained by using cells from weak and strong responders, respectively. 
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Fig. 13. CD4+ T cell proliferation induced by different virosome formulations. CD4+ and CD14+ cells 
isolated from healthy donors‘ blood were cocultured in the absence of stimulation (Neg) and in 
presence of Mart-FCIRIV, empty CIRIV fused with empty liposomes (FCIRIV) and empty CIRIV 
(CIRIV). On day 5 of culture cells were pulsed with 3H-thymidine for 18 hours and then proliferation 
was measured as 3H-thymidine incorporation. Panel A and B represent results of cell cultures from two 
healthy donors. 
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2. Mart-FCIRIV induce gene expression and secretion of cytokines consistent with a  
T helper 1 profile. 
To verify whether the observed CD4+ T cell response was T helper 1 (Th1) or T helper 2 
(Th2) in nature, we then addressed IFN-γ and IL-4 cytokine gene expression upon 
stimulation of CD4+/CD14+ cell cocultures with CIRIV, FCIRIV and Mart-FCIRIV or in 
absence of stimulation. Cells were harvested on day 1 and 2 of culture, total RNA was 
extracted and specific transcripts were quantified by real time PCR.  IFN-γ gene 
expression was not detectable in cells from unstimulated cultures. In contrast, in cells 
stimulated with different concentrations of CIRIV, FCIRIV or Mart-FCIRIV a high 
expression of IFN-γ gene was observed on days 1-2 of culture. Figure 14, panels A and C 
reports data from two different donors. On the other hand IL-4 gene expression was 
undetectable in all culture conditions tested.  
IFN-γ and IL-4 secretion was then tested by ELISA in supernatants harvested on day 2 
from CD4+/CD14+ cell cultures performed in the presence of the different influenza 
virosome formulations. IFN-γ  was found to be produced to different extents by CIRIV, 
FCIRIV or Mart-FCIRIV stimulated but not control cultures from different donors (Figure 
13, panels B and D). Instead, IL-4 was undetectable in supernatants from all cultures. 
 
3. Stimulation by Mart-FCIRIV results in increased percentages of CXCR3+ CD4+ cells. 
 
To further validate the T helper 1 nature of virosome induced CD4+ T cell responses we 
comparatively addressed the percentage of CD4+ cells expressing CXCR3 in presence of 
Mart-FCIRIV, in presence of liposomes (L) or in absence of any stimuli (Neg). CD4+ and 
iDC from healthy donors were cocultured in presence of different dilutions of either reagent 
or in the absence of stimulation. On day six of culture CD4+ cells were tested by flow 
cytometry for CXCR3 expression. Data reported in figure 15, show that stimulation with 
Mart-FCIRIV (panels A and B) resulted in increased percentages of CD4+ cells expressing 
CXCR3 as compared to culture in presence of liposomes (panels C and D) and culture in 
absence of any stimulation (panel E). 
Taken together, these results indicate that Mart-FCIRIV, same as IRIV, possess a high 
capacity to induce CD4+ T cell responses characterized by a T helper 1 profile. 
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Fig. 14. IFN-γ gene expression (panels A and C) and secretion (panels B and D) in Mart – FCIRIV stimulated 
CD4+ / CD14+ cell cocultures. CD4+ T cells and CD14+ cells were isolated from healthy donor’s blood and 
cocultured in presence of Mart – FCIRIV), empty CIRIV fused with empty liposomes (FCIRIV), empty CIRIV 
(CIRIV) and in absence of any stimuli (Neg) at indicated dilutions. Cells were harvested on day 1 (d1, black 
bars) and on day 2 (d2, hatched). Total RNA was extracted from each sample and IFN-γ (panels A, C) gene 
expression analysed by real time PCR. 
IFN-γ protein concentrations were determined in supernatants harvested on day 2 by cytokine specific ELISA 
(panels B and D). IL-4 gene expression and secretion was also addressed, but was not detectable neither in 
real time PCR nor in ELISA. Results of cell cultures from two donors (panels A and B and panels C and D 
respectively ) are presented. 
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Fig.15. Mart
 
– FCIRIV increase the percentage of CXCR3 expressing CD4+ cells within the CD4+ T cell 
population. CD4+ T cells were cocultured with autologous iDC in presence of Mart– FCIRIV (panel A: 1:100 and 
panel B: 1:300), Liposomes (L, panel C: 1:100 and panel D: 1:300) and in absence of any stimuli (Neg, panel E). 
On day six of culture cells were phenotyped for the expression of CD4 and CXCR3 by flow cytometry. 
Dot plots are representative of data from two different experiments. Percentages of CXCR3+CD4+ cells and 
CXCR3-CD4+ cells are shown. 
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4.  Mart-FCIRIV adjuvance in L27Melan-A/Mart-126-35  specific CTL induction 
Mart-FCIRIV adjuvance in L27Melan-A/Mart-126-35 specific CTL induction was assessed by 
cytotoxicity assays and pentamer staining. First, cytotoxicity assays were performed by 
using peptide pulsed HLA-A0201+ target cells that do not express Melan-A/Mart-1 gene. 
In a second step, to evaluate the capacity of induced L27Melan-A/Mart-126-35 specific CTL 
to recognize the naturally expressed epitope and to lyse Melan-A/Mart-1 expressing tumor 
cells, cytotoxicity assays were performed with tumor target cells that express both, HLA-
A0201 and Melan-A/Mart-1 gene. Third, CD4+ T cell independent adjuvance of Mart-
FCIRIV was addressed by CTL induction experiments in the absence of CD4+ T cells. 
 
 
 
A. Mart-FCIRIV induce L27Melan-A/Mart-126-35 specific CTL 
Peripheral blood CD14- cells from healthy donors were cocultured with autologous 
immature dendritic cells (iDC) in presence of L27Melan-A/Mart-126-35 in solution or 
encapsulated in FCIRIV. After IL-2 supplementations (see materials and methods) cells 
were phenotyped and restimulated with peptide pulsed iDC on day 6-7 of culture. 
Additional phenotypes and cytotoxicity assays were performed between days 13 to 15 
after further IL-2 supplementations. HLA-A0201+ T2 cells exogenously pulsed with 
synthetic epitopes were used as target cells. In the presence of limiting amounts of peptide 
(0.1-1 µg/ml), a significantly improved CTL induction was observed when synthetic 
epitopes were encapsulated into FCIRIV as compared to soluble reagents. Representative 
results obtained by using cells from two different donors are shown in Fig. 16 (panels A 
and B). HLA-A0201/L27Melan-A/Mart-126-35 pentamer staining data were also consistent 
with a higher immunogenicity of the peptide included in virosomes as compared to the 
soluble reagent (Figure 17). Occasionally, however, discrepancies between cytotoxic 
capacity and tetramer staining were also observed, as previously described [3].  
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Fig. 16. Mart–FCIRIV mediated induction of CTL specific for L27Melan-A/Mart-1 26-35. 
CD8+ cells and CD4+ cells were isolated from peripheral blood of two healthy donors and cocultured 
together with autologous immature dendritic cells (iDC) in presence of L27Melan-A/ Mart-126-35 and of Mart-
FCIRIV (stock: 100µg peptide/ml) at 0.25µg peptide/ml. IL-2 supplementation was performed as described in 
Materials and Methods. On day 7 or 8 cell cultures were restimulated with peptide pulsed irradiated iDC in 
presence of IL-2. Cytotoxicity assays were performed on day 16 of culture. Cytotoxicity assay results refer to 
cultures from two donors (panels A  and B) with control peptide pulsed (open symbols) and L27Melan-A/Mart-
1 26-35 pulsed (filled symbols), HLA0201+ target cells in presence of L27 Mart-1/Melan-A 26-35 (triangles) or 
Mart–FCIRIV (squares) primed CD8+/CD4+/iDC cocultures.  
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Fig. 17. Mart-FCIRIV increase the percentage of L27Melan-A/Mart-126-35 specific CTL as 
compared to L27Melan-A/Mart-126-35 in solution. CD14- cells were isolated from healthy donor’s 
blood and cocultured with autologous iDC in presence of 1µg L27Melan-A/Mart-126-35 / ml 
formulated either as soluble peptide as such (Mart-PEPTIDE, panel A) or as encapsulated 
peptide in FCIRIV (Mart-FCIRIV, panel B). After IL-2 supplementations and one restimulation 
with peptide pulsed iDC (see materials and methods) cell cultures were phenotyped for the 
expression of CD8 and TCR specific to L27Melan-A/ Mart-126-35 by anti-CD8 FITC / L27Melan-
A/ Mart-126-35 pentamer PE double staining. Numbers represent percentages of cells within 
each quadrant.  
13.16 
56.23 
In bold, percentages of pentamer positive cells within the CD8+ cell population are 
presented. 
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B. L27Melan-A/Mart-126-35 specific CTL induced by Mart-FCIRIV are able to lyse  
HLA-0201+ melanoma cells expressing Melan-A/Mart-1 
 
Peptide specific cytotoxicity demonstrated that CTL induced by Mart-FCIRIV recognized 
exogenously pulsed HLA-A0201+ target cells. 
We then addressed recognition of the naturally expressed Melan-A/Mart-1 TAA by 
performing cytotoxicity assays using, as targets, HLA-A0201+ HBL melanoma cells 
constitutively expressing the Melan-A/Mart-1 gene. 
CD14- cells from two donors were cocultured with autologous iDC in the presence of 
antigenic peptide in solution or contained into influenza virosomes. Cytotoxicity assays 
showed that CTL from either donor (figure 18, panel A and B) induced by Mart-FCIRIV 
were indeed capable of recognizing the native Melan-A/Mart-1 epitope, as expressed by 
HLA-A0201+ HBL melanoma cells. Most importantly, cytotoxic activities were in both 
cases significantly higher than those mediated by L27Melan-A/Mart-126-35 specific CTL 
induced by soluble peptides. 
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Fig. 18. Cytotoxicity of Mart-FCIRIV stimulated effector cells against HLA-A0201+ HBL tumor cells 
expressing Melan-A/Mart-1. CD14- cells were isolated from blood of two healthy donors (panels A and B) 
and cocultured with autologous immature dendritic cells (iDC) in presence of L27Melan-A/ Mart-126-35  in 
solution (triangles) and of Mart-FCIRIV (squares) at 1µg peptide/ml concentration.  
IL-2 supplementation was performed as described in Materials and Methods. On day 6 (panel A) or 7 
(panel B) cell cultures were restimulated with peptide pulsed irradiated autologous iDC in presence of IL-2. 
Cytotoxicity assays were performed, using the Melan-A/Mart-1 expressing HLA-A0201+ tumor cell line HBL 
(filled symbols) and the Melan-A/Mart-1 negative, HLA-A0201+ NA-8 cell line (open symbols, negative 
control) as target cells.  
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C. CD4+ T-cell independent CTL adjuvance of Mart-FCIRIV 
 
Taken together, these data indicate that Mart-FCIRIV are highly immunogenic, possibly 
due to their capacity to stimulate specific CD4+ T-cell responses, in accordance with our 
study on IRIV mediated CTL adjuvance. However, work by other groups indicates that 
CD4 T-cell independent adjuvance may also be related to the capacity of virosomes to 
efficiently deliver antigens into APC cytosol [12,36]. This property results from receptor 
mediated endocytosis and fusion of influenza virosomes with endosomes, both 
mechanisms dependent on viral hemagglutinin [37-39]. To address the issue of CD4+ T 
cell independent virosome adjuvance, we stimulated purified CD8+ T cells with L27Melan-
A/Mart-126-35 peptide encapsulated in FCIRIV (Mart-FCIRIV) or in solution, in the absence 
of CD4+ cells. 
Both, pentamer staining (Fig. 20) and cytotoxicity assays (Fig. 19) clearly indicated that 
stimulation of CD8+ cells with Mart-FCIRIV in the absence of CD4+ T-cells also powerfully 
promoted the induction of  antigen specific CTL, at low (0.25-0.75 µg/ml) peptide 
concentrations.  
These results demonstrate that peptide containing influenza virosomes, in addition to 
CD4+ T cell activation, mediate CD4+ T cell independent CTL adjuvance. 
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Fig. 19. Mart-FCIRIV enhanced CD4+ T cell independent L27Melan-A/Mart-126-35 specific CTL induction.  
CD8+ T cells were isolated from peripheral blood of a healthy donor and cocultured with autologous iDC in 
presence of L27Melan-A/Mart-126-35 in solution (triangles) or Mart–FCIRIV (squares). After IL-2 supplementation 
(see Material and Methods) and one restimulation with irradiated monocytes cytotoxicity assays were performed 
using control peptide pulsed (open symbols) or L27Melan-A/Mart-126-35 pulsed (filled symbols) HLA-A0201+ 
target cells. Panels A and B display CTL cytotoxicity induced by each formulation corresponding to 0.25µg 
peptide/ml (panel A) and 0.75µg peptide/ml (panel B) assayed on day 16. CTL induction experiments with CD8+ 
T cells from additional cultures from two different donors provided similar results. 
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Fig. 20. Enhanced L27Melan-A/Mart-126-35 specific CTL induction by Mart-FCIRIV in absence of CD4+ T 
cells, as demonstrated by pentamer staining. Peripheral CD8+ T cells from one healthy donor were 
cocultured with autologous iDC in presence of L27Melan-A/Mart-126-35 or Mart-FCIRIV. After IL-2 
supplementation (see Material and Methods) and one restimulation with irradiated monocytes cells 
were phenotyped for the expression of CD8 and L27Melan-A/Mart-126-35 specific TCR by anti-CD8 FITC/ 
L27Melan-A/Mart-126-35 pentamer PE double staining. Panels A , B, C and D display results of cultures 
induced by each formulation corresponding to 0.25µg peptide/ml (panels A and C) and 0.75µg 
peptide/ml (panels B and D) assayed on day 13. CTL induction experiments with CD8+ T cells from 
two additional donors provided similar results. Numbers indicate percentages of cells within each 
quadrant. 
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PART 3: INFLUENZA VIROSOMES AND CD4+CD25+ T REGULATORY CELLS  
 
Effects of influenza virosomes on CD4+CD25+ T regulatory cell mediated suppression of 
immune responses were also addressed. CD4+CD25+ T regulatory cells have been 
described to play a key role in maintaining peripheral tolerance to self-antigens [40,41]. 
Moreover, indications that CD4+CD25+ T regulatory cells represent a hindrance to 
antitumor immune responses are increasingly reported [42,43]. Although underlying 
mechanisms of CD4+CD25+ T regulatory cell mediated suppression are still not clarified, it 
is mostly accepted that CD4+CD25+ T regulatory cells are activated through TCR 
triggering, and following activation, act in an unspecific way [44,45] . 
We addressed CIRIV CTL adjuvance in presence of different CD4+ T cell subsets as 
shown in Fig. 21. IM58-66 peptide admixed with CIRIV resulted in higher induction of IM58-66 
specific CTL (8% of CD8+ cells, panel B) as compared to IM58-66 peptide alone (5.66%, 
panel A) in presence of bulk CD4+ T cells.  
In presence of purified CD4+CD25+ T regulatory cells induction of IM58-66 specific CTL by 
either formulation was low (0.64% without CIRIV, panel C; 0.48% with CIRIV, panel D) and 
no CIRIV adjuvance could be observed. In presence of purified CD4+CD25- cells induction 
of IM58-66 specific CTL was equal between the two formulations (9.39%, panel F and 9.8%, 
panel E, respectively) and similar to CTL induction by IM58-66 admixed with CIRIV in 
presence of bulk CD4+ T cells (8%, panel B). These preliminary results suggest that CIRIV 
provide adjuvance in presence of the whole CD4+ T cell population, inclusive CD4+CD25+ 
T regulatory cells. Recent studies reported overcoming of CD4+CD25+ T regulatory cell 
mediated immunosuppression by toll like receptor ligands [46-48]. Investigations on 
underlying mechanisms suggested an important role of IL-6 in rendering CD4+CD25- cells 
unresponsive to CD4+CD25+ T regulatory cells [47]. Thus, we tested whether influenza 
virosomes induce IL-6 gene expression in PBMC cultures. As shown in Fig. 22,  IL-6 gene 
expression was higher in PBMC cultured in presence of IRIV or PHA than in PBMC 
cultured without any stimuli, as demonstrated in PBMC cultures from two donors (panels A 
and B). Comparing these results between the two different PBMC cultures, IL-6 gene 
expression followed different kinetics. In one case IRIV induced IL-6 gene expression 
reached its maximum after 29 hours of stimulation (grey bars, panel A), in the second case 
after 15 hours of stimulation (black bars, panel B). IL-6 gene expression was at highest in 
presence of PHA. In each case PHA induced IL-6 gene expression reached its maximum 
after 15 hours (black bars) of stimulation.
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Fig. 21. CIRIV CTL adjuvance in presence of different CD4+ T cell subsets. CD8+ cells were 
cocultured with iDC and either CD4+ cells (Fig.  Panels A and B) or CD4+ CD25+ T regulatory 
cells (Fig.  Panels C and D) or CD4+CD25- cells (Fig. Panels E and F). These cocultures were 
performed in presence of IM58-66 (1µg/ml) alone (Fig. panels A, C, E) and in presence of IM58-66 
(1µg/ml) admixed with CIRIV 1:200 (Fig. Panels  B, D, F). On day 7 of culture cells were 
phenotyped by anti-CD8 FITC/ IM58-66 tetramer PE double staining. Numbers represent 
percentages of cells within each quadrant, in bold percentages of  pentamer positive CD8+ cells  
within the CD8+ cell  population are shown. 
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Fig. 22. IRIV induce IL-6 gene expression in PBMC cultures. PBMC from two donors (panels A and B) 
were cultured in presence of IRIV (diluted 1:100 and 1:200 panel A, 1:100 panel B), in presence of PHA 
(1µg/ml) and in absence of any stimuli (Neg). After 15 (black), 29 (grey) and 48 (white) hours cells were 
harvested. Following RNA extraction and reverse transcription, gene expression of IL-6 was measured 
by real time PCR. 
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DISCUSSION 
 
The goal of this thesis work was to characterise immune responses elicited by 
immunopotentiating reconstituted influenza virosomes (IRIV) and to evaluate influenza 
virosome adjuvance in relation to induction of HLA class I restricted cytotoxic T 
lymphocytes (CTL). The relevance of these objectives is underlined by the low number of 
adjuvants approved for human use and the general need of adjuvants that enhance 
cellular immune responses against antigens from  intracellular pathogens and tumors 
[2,49]. This work may also contribute to the evaluation of influenza virosomes as adjuvants 
for future clinical trials, aiming to enhance melanoma associated antigen specific CTL 
responses. We addressed these objectives by testing different formulations, all produced 
by Pevion Biotech Ltd.: IRIV, IRIV admixed with HLA class I restricted peptides (either 
IM58-66 or Melan-A/Mart-127-35), chimeric IRIV (CIRIV), chimeric IRIV fused to empty 
liposomes (FCIRIV) and FCIRIV encapsulating the HLA class I restricted L27Melan-A/Mart-
126-35 peptide. All experiments were performed in vitro by using peripheral blood 
mononuclear cells (PBMC) from healthy donors.  
IRIV and FCIRIV induced a T helper 1 like CD4+ T cell proliferation characterized by IFN-
γ expression and increased frequencies of CD4+ T cells expressing CXCR3. The extent of 
these proliferative responses displayed a marked variability between different donors, but 
all healthy donors responded. Further dissection into CD45RA+ and CD45RO+ cell 
subsets demonstrated that proliferating cells were CD4+CD45RO+ cells. In addition, no 
major cell proliferation could be observed upon IRIV supplementation to cell cultures 
depleted of antigen presenting cells nor to cord blood mononuclear cell cultures. Taken 
together, these results demonstrate that influenza virosomes induce antigen triggered 
proliferation of CD4+ T cells displaying a memory phenotype. Although identity of the 
proliferation inducing antigen(s) has not been formally addressed, HLA class II restricted 
hemagglutinin epitopes presumably provide the major contribution, as influenza virus 
derived neuraminidase is only marginally present on influenza virosomes. Moreover, 
liposomes devoid of viral proteins did not induce cell proliferation. 
In addition to IFN-γ, IRIV induced expression of TNF-α, GM-CSF and the chemokines MIG 
(CXCL9), Rantes (CCL5) and IP-10 (CXCL10). MIG, Rantes and IP-10 are reported to 
attract mainly T lymphocytes [24,25]. Interestingly, MIG and IP-10 share as receptor 
CXCR3 [27], which is also expressed on IRIV and Mart-FCIRIV stimulated CD4+ T cells. 
Although the functional relevance of these chemokines has not been addressed in our 
studies, this pattern suggests that they may play an important role in the recruitment of  
 60 
T lymphocytes, thus facilitating IRIV elicited immune responses. 
Regarding IRIV effects on immature dendritic cells, no upregulation of surface maturation 
markers could be observed in the absence of other cell types. This finding is consistent  
with a previous study on influenza virus and subunit vaccines in human cell cultures [50]. 
On the other hand, one study on influenza virosomes in murine cell cultures demonstrated 
that OVA encapsulating influenza virosomes may directly induce maturation of dendritic 
cells .Whereas no direct induction of dendritic cell maturation could be observed in our 
hands, supernatants derived from IRIV stimulated PBMC cultures favoured maturation of 
dendritic cells as demonstrated by increased surface expression of HLA- class I 
molecules, CD86 costimulatory molecules and CD83. These results suggest that IRIV 
induce expression and secretion of cytokines in PBMC cultures that favour dendritic cell 
maturation. Maturation of dendritic cells has been shown to correlate with improved 
antigen presentation and costimulation [51]. These findings are consistent with increased 
expression of IFN-γ, TNF-α and GM-CSF in IRIV stimulated PBMC cultures, as these 
cytokines have been reported to play a role in development, differentiation and maturation 
of APC [52-54]. The capacity of IRIV and FCIRIV to elicite CD4+ T cell proliferation, a T 
helper 1 characteristic cytokine profile, and to promote antigen presentation may be 
relevant for the enhancement of HLA class I restricted CTL induction.  
Indeed, tetramer/pentamer staining and cytotoxicity assays demonstrated enhanced 
induction of CTL specific for IM58-66, Melan-A/Mart-127-35 and L27Melan-A/Mart-126-35 using 
IRIV admixed with peptides or FCIRIV encapsulating peptides as compared to peptides 
admixed with liposomes or  peptides alone. Taken together, these findings show a marked 
influenza virosome mediated CTL adjuvance in vitro. Importantly, this could be 
demonstrated not only in relation to the IM58-66 epitope but also in relation to the less 
immunogenic melanoma associated Melan-A/Mart-127-35 epitope. Quantification of specific 
CTL, as addressed by multimer staining, suggests that stimulation with IRIV admixed with 
peptides results in at least five to ten times higher numbers of specific CTL as compared to 
liposomes admixed with peptides and to peptides in absence of any other stimuli. 
The finding of IRIV mediated in vitro CTL adjuvance prompted the investigation on 
underlying mechanisms. Given the formulation of IRIV admixed with peptides, the 
observed IRIV CTL adjuvance is likely to be solely attributable to IRIV immunogenic 
properties and independent of IRIV delivery capacities. 
As our studies on IRIV showed immune responses in the absence of antigenic peptides 
and demonstrated proliferation of antigen experienced CD4+ T cells, we addressed the 
importance of CD4+ T cell help in IRIV mediated CTL adjuvance. Irradiation of CD4+ T 
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cells resulted in abrogation of IRIV mediated CTL adjuvance as demonstrated by tetramer 
staining  addressing IM58-66 specific CTL induction. This observation demonstrates that 
IRIV mediated CTL adjuvance acts through CD4+ T cell activation. 
With regard to CD4+ T cell help in CTL generation, at least two mechanisms have been 
described. One is acting through APC activation by  cell : cell contact dependent CD40 
Ligand – CD40  interaction between activated CD4+ T cells and APC, the other by CD4+ T 
cell mediated cytokine secretion, directly favouring expansion of activated CTL. Finally, 
also a CD40-independent  but cell : cell contact dependent pathway has been suggested 
[55]. In our system, preliminary results of transwell experiments demonstrated no 
difference in IRIV enhanced CTL induction in the presence or absence of contact between 
CD4+ T cell/ APC and CD8+ T cell/ APC cocultures. As only physical cell : cell contact 
was inhibited, but not diffusion of  soluble factors, this observation suggests that cytokines 
play a key role in IRIV mediated CTL adjuvance. Again, the cytokines addressed in this 
work, might all contribute to IRIV mediated CTL adjuvance, in that they favour APC 
maturation (TNF-α, IFN-γ, GM-CSF) or, in the case of IL-2, act as growth factors directly 
on activated lymphocytes. 
Obviously, the requirement of antigen triggered CD4+ T cell activation and the absence of 
direct  induced APC maturation suggest that IRIV CTL adjuvance is driven by adaptive and 
not innate immune responses, e.g. through toll like receptor ligand triggering [4]. Moreover, 
the non-responsiveness of naive T lymphocytes indicates that IRIV CTL adjuvance 
depends on previous exposures to or vaccinations against influenza virus. Finally, these 
prerequisites also point to the immunocompetence of vaccinees. As CD4+ T cell memory 
against influenza is usually developed during childhood, use of IRIV as CTL adjuvant in 
cancer immunotherapy should not be hampered from this point of view. In contrast, 
defective immunocompetence may  be observed in advanced tumors. 
In this regard it should be noted that tumor induced immunosuppression increases with 
tumor size and stage, leaving a time window  for early treatment, following surgical tumor 
resection. In relation to infectious diseases, IRIV CTL adjuvance may  be at least in part 
abrogated in AIDS patients due to HIV infection and subsequent destruction of CD4+ T 
cells. 
Overall, our results suggest that IRIV induce adaptive CD4+ T cell responses which, 
presumably through cytokines, enhance adaptive CD8+ T cell responses induced by the 
HLA class I restricted epitope of interest.  
Given the possibility to combine influenza virosome immunogenic capacities with their 
delivery capacities, we tested L27Melan-A/Mart-126-35 specific CTL induction by FCIRIV 
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containing L27Melan-A/Mart-126-35 peptides. This formulation, as IRIV, was produced by 
Pevion Biotech Ltd. Regarding delivery capacities, influenza virosomes have been shown 
to be uptaken by APC through receptor mediated endocytosis and to fuse with the 
endosomal membrane, both processes triggered by influenza virus derived hemagglutinin 
[6]. Virosome fusion with the endosomal membrane hypothetically  results in release of 
encapsulated content into the cytosol [6]. This intracellular delivery of HLA class I 
restricted epitopes is quite different from the exogenous application of peptides as such 
and may be important  for HLA class I presentation. 
Indeed, fusion competence of influenza virosomes encapsulating a murine CTL epitope of 
the influenza virus nucleoprotein (NP) has been shown to be required in vivo for efficient 
induction of a class I MHC-restricted CTL response against influenza-infected cells [12]. 
Enhancement of L27Melan-A/Mart-126-35 specific CTL induction in presence of Mart-FCIRIV 
as compared to L27Melan-A/Mart-126-35 peptides in solution could be demonstrated by 
cytotoxicity assays and pentamer staining. Importantly, this adjuvance could be observed 
in cytotoxicity assays using as target cells HBL, HLA-A0201+ tumor cells that constitutively 
express Melan-A/Mart-1. This observation demonstrates that CTL primed by Mart-FCIRIV 
are able to recognize the native antigen, and, upon recognition, to lyse tumor cells.  
In a minority of cases, pentamer staining did not correlate with cytotoxicity assay results. 
Such discrepancies in general have been described previously [3]. In such cases we 
rather relied on cytotoxicity assay results as they are functionally representative for 
influenza virosome CTL adjuvant capacities. Regarding the cases without discrepancies, 
pentamer staining results suggest that CTL adjuvance displayed by FCIRIV encapsulating 
peptides lies approximately in the same range as described for IRIV admixed with 
peptides. However, in contrast to IRIV admixed with peptides, Mart-FCIRIV displayed 
remarkable CTL adjuvance in absence of CD4+ T cells as demonstrated by pentamer 
staining. This CD4+ T cell independent CTL adjuvance is likely attributable to influenza 
virosome delivery capacities. A second explanation might suggest direct effects of Mart-
FCIRIV on APC. Such direct effects however would be independent of APC maturation, 
given the fact that Mart-FCIRIV were unable to induce upregulation of maturation markers 
on APC within 24 hours of culture.  
A third explanation for the mechanism of CD4+ T cell independent adjuvance of FCIRIV 
might be represented by their capacity to protect the encapsulated peptide from enzymatic 
degradation by serum or cell associated peptidases. In our system this is rather unlikely as 
L27Melan-A/Mart-126-35, our model peptide, is relatively resistant to  
enzymatic degradation [56].  
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In addition, the in vitro cell culture system provides immediate access of peptides to APC 
in conditions with low percentages of human serum.  
The observation of both, T helper 1 CD4+ T cell activation and CD4+ T cell independent 
CTL adjuvance by Mart-FCIRIV suggests an advantage of this formulation as compared to 
IRIV admixed with peptides. This advantage, if related to influenza virosome delivery 
capacities, might result in a lower amount of peptides required to induce a strong CTL 
response. The advantage may become more important in conditions where memory CD4+ 
T cells specific to influenza virosome antigens are in short supply or suppressed. Further, 
peptide protection from enzymatic degradation could be of major relevance in vivo. Given 
the route of subcutaneous administration, Langerhans cells are most probably the first 
APC that would uptake the administered antigen. However, far higher numbers of 
fibroblasts are present. In vitro, fibroblasts have been shown to be able to degrade 
antigenic peptides [57].  
  
Our in vitro studies have demonstrated remarkable CTL adjuvance of two influenza 
virosome formulations as related to the HLA class I restricted epitopes IM58-66 and  
Melan-A/Mart-127-35 in case of IRIV and L27Melan-A/Mart-126-35 in case of Mart-FCIRIV. 
These epitopes have not been addressed by other experimental studies on influenza 
virosome formulations, which were mostly performed in animal models. The relevance of 
our data, in the context of future clinical trials, is represented by the use of human cell 
cultures. The drawback, of all in vitro studies, is most obviously represented by the lack of 
the cellular complexity present in vivo.  
On the other hand, CTL adjuvance in vivo has been proven for influenza virosomes 
encapsulating an epitope of the Influenza virus nucleoprotein [12], chimeric influenza 
virosomes encapsulating the HCV core 132 peptide [11]  and influenza virosomes 
encapsulating OVA protein [13].  
Regarding underlying mechanisms of Influenza virosome CTL adjuvance, it is of interest to 
address influenza virosome effects on CD4+CD25+ T regulatory cell mediated 
suppression as well. These cells have been reported to play an important role in 
maintenance of peripheral tolerance to self antigens [40,41]-. As differentiation tumor 
associated antigens are self antigens, efficient induction of antitumor immune responses 
might be hampered by CD4+CD25+ T regulatory cells. A few studies have described a 
overcoming of CD4+CD25+ T regulatory cell mediated suppression by toll like receptor 
ligands in murine models [46-48]. IL-6 has been proposed to render CD4+CD25- cells 
unresponsive to CD4+CD25+ T regulatory cells [47]. The preliminary data of our study 
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indicate that influenza virosomes induce IL-6 gene expression in PBMC cultures. 
Furthermore, in vitro IRIV mediated CTL adjuvance related to IM58-66 in the presence of the 
whole CD4+ T cell population reached the same levels of CTL expansion detectable in 
CD4+CD25+ T regulatory cell depleted CD4+ T cell population (CD4+CD25- cells). In 
presence of a CD4+ T cell population consisting only of CD4+CD25+ T regulatory cells no 
CTL induction could be observed with either formulation. These results suggest the 
possibility that mechanisms underlying IRIV mediated CTL adjuvance might include effects 
counteracting physiological CD4+CD25+ T regulatory cell mediated immunosuppression. 
 
The evaluation of a pharmaceutical product requires not only efficacy but also toxicity 
studies. In this regard, the use of peptides encapsulated in FCIRIV or IRIV admixed with 
peptides in future clinical trials is likely to provide the regulatory advantage that IRIV are 
already approved as adjuvants for hepatitis A vaccination and as subunit vaccine for 
influenza vaccination.  
 
In summary, this work demonstrates that two different influenza virosome formulations 
provide CTL adjuvance in relation to IM58-66 and HLA class I restricted epitopes of the 
tumor associated antigen Melan-A/Mart-1. These results encourage further evaluation of 
influenza virosome formulations in vivo, addressing induction of CTL specific for 
melanoma associated antigens and therapeutic efficacy against melanoma.  
Influenza virosome formulations encapsulating HLA class I restricted peptides would have 
the advantage of both, T helper 1 CD4+ T cell activation and  CD4+ T cell independent 
CTL adjuvance, presumably due to  intracellular delivery and protection of peptides from 
degradation. 
Finally, although not in our scope, the observation of IRIV IM58-66 CTL adjuvance might be 
important with regard to vaccination against influenza. Influenza virosomes in combination 
with the influenza HLA class I restricted epitope IM58-66 might provide both, humoral and 
CTL responses against influenza viruses. In addition, given the fact that HA and NA are 
highly variable antigens of influenza virus [58-60], a more conserved  epitope might be of 
high relevance in case of lack of memory to newly evolved HA or NA variants. 
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